Posted by SalArmy4me on August 31, 2001, at 20:16:33
In reply to Does Amisulpride help with depression, anxiety?, posted by Margit on August 31, 2001, at 20:01:37
Its worth a try. Order it from Farmacia Cerati: http://www.farmaciacerati.it/
Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord. 1998;48:47-56:
"In a multicentre, double blind, parallel group study 281 patients with DSM III-R diagnosis of dysthymia or a single episode of major depression in partial remission were randomised to 3 months of treatment with amisulpride 50 mg/day or fluoxetine 20 mg/day. The baseline Montgomery and Asberg Depression Rating Scale (MADRS) total score was reduced by at least 50% in 74.1% of patients (103/139) with amisulpride and 67.4% (87/129) with fluoxetine (P =0.230). No significant differences between treatment groups were found in the reductions in mean total score with the MADRS, Widlocher psychomotor retardation scale, Sheehan disability scale, and CGI. Anxiety measured by HAM-A total mean score decreased significantly more with amisulpride (63%) than with fluoxetine (54%; P = 0.021). There were 13 dropouts due to adverse events with amisulpride and ten with fluoxetine. The number of patients reporting at least one adverse event was similar in the two groups (amisulpride 47.5%; fluoxetine 40.9%)..."
Rihmer, Zoltan. Dysthymic disorder: implications for diagnosis and treatment. Current Opinion in Psychiatry. 12(1):69-75, January 1999:
"As dysthymic disorder is a chronic condition, it has been pointed out that the patients need full-dose maintenance pharmacotherapy, preferably with new compounds, which are much better tolerated. Amisulpride (an atypical neuroleptic, which in low dose acts as a dopamine enhancer) has also been found to be quite effective in dysthymic disorder..."
Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride Study Group. Amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord 1997; 43:95-103:
"Amisulpride, a selective antagonist of D2 and D3 dopamine receptors, acts preferentially on presynaptic receptors increasing dopaminergic transmission at low doses. In a multicentre, 6 months, placebo-controlled trial, amisulpride (50 mg/daily) was compared to imipramine (100 mg/daily) in the treatment of patients with DSM-III-R criteria for primary dysthymia, dysthymia with major depression or major depression in partial remission. A total of 219 patients were included. Both analyses (intention-to-treat and "per protocol' analysis) detected significant differences between groups (active treatment vs. placebo) on all main rating scales (CGI, MADRS, ERD, and SANS). The number of patients reporting at least one adverse event was higher in the imipramine group than in the two other, mainly due to anticholinergic effects. Endocrine symptoms were more frequent in female patients treated with amisulpride. These results confirm the interest of a drug acting on dopaminergic transmission such as amisulpride in the treatment of depressed patients..."
poster:SalArmy4me
thread:77159
URL: http://www.dr-bob.org/babble/20010828/msgs/77162.html